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Cerebral Hyperperfusion Syndrome: The Dark Side of Carotid Endarterectomy
P. De Rango*
Division of Vascular and Endovascular Surgery, University of Perugia, Hospital S. M. Misericordia, Loc. S. Andrea delle Fratte, 06134 Perugia, ItalyCarotid endarterectomy (CEA) is the most frequently per-
formed surgical procedure to prevent stroke inWestern countries.
Nevertheless, despite the widespread use and the technical
simplicity, CEA is still today a not totally known procedure and
may lead to unpredictable ﬁndings such as cerebral hyper-
perfusion syndrome (CHS) deﬁned as “unexpected increase in
cerebral blood ﬂow >100% potentially leading to cerebral
hemorrhage”. Even if rare (nearly 10% of CEA) CHS is an upsetting
complication with a catastrophic burden, especially when occur-
ring in patients with asymptomatic carotid disease. Generally
believed to be related to the lack of cerebral autoregulation in
previously hypoperfused cerebral areas and favoured by high
blood pressure, CHS remains largely unknown regarding causes,
risk factors, clinical consequence, prevention and treatment. As of
today, the only way to manage CHS is by close monitoring and
aggressive use of anti-hypertensive drugs to decrease excessive
cerebral perfusion.
A step forward in the knowledge of CHS has been provided in
this issue of EJVES by the Netherlands experience of Ponnekamp
et al., who suggested to introduce an additional measurement of
cerebral blood ﬂow with transcranial Doppler (TCD) in the ﬁrst 2 h
after CEA to more reliably and not-invasively identify patients at
risk of postoperative CHS.1 In over 184 patients (87% symptomatic)
undergoing CEA under general anaesthesia, the authors found that
positive predictive value (PPV) of CHS development was signiﬁ-
cantly higher in TCD measurements of cerebral ﬂow performed
postoperatively (41%) with respect to the most commonly
employed intra-operative TCD measurements (PPV 13%). Authors
suggested that postoperative TCDmeasurements allowed complete
weaning from anaesthetic drugs and their confounding effect on
cerebral blood ﬂow: strict intravenous anti-hypertensive manage-
ment could therefore be limited to individualised subgroups of CEA
patients at reliably high risk of CHS avoiding unnecessary anti-
hypertensive overtreatment/monitoring in most CEA patients.
These interesting ﬁndings raise a couple of issues: ﬁrst, the reli-
ability of TCD, recognised as an operator-dependent technique, for
identifying CHS outside highly experienced ultrasound vascular
laboratories such as that of the Netherland group and second, the
relevance of the delayed (postoperative) TCD measurements forDOI of original article: 10.1016/j.ejvs.2011.12.024.
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doi:10.1016/j.ejvs.2012.01.012patients frequently receiving CEA under local anaesthesia where
the confounding effect of anaesthetic drugs on cerebral ﬂowmay be
irrelevant.
The occurrence of uncontrolled high blood pressure (HP) after
CEA is more common and often anticipates CHS, but it is similarly
unexplained and difﬁcult to predict and manage. Pennekamp et al.
found that all the patients who developed CHS suffered from HP
that involved about one-ﬁfth of overall CEA patients and was
similarly better predicted by postoperative rather than intra-
operative TCD values.1
A worrying issue is that, even if we could reliably identify
patients at risk of CHS or HP, we do not know how to best manage
these patients: the targets for blood pressure levels after CEA (to
prevent postoperative ischaemic stroke risk and at the same time
avoid cerebral hyperperfusion) are not well deﬁned and largely
uncertain in current guidelines.2
Cardiac complications are the main reasons for mortality and
morbidity in carotid patients: cardiac and carotid diseases share
many risk factors, lifestyle prevention measures and therapeutic
drugs. Today, CEA patients may beneﬁt from advancements in
medical therapy ﬁrstly introduced for cardiac disease. Nevertheless,
the potential of favouring intracerebral bleeding from statins and
anti-platelets is a reason for concern as these drugs are today more
aggressively used in patients with carotid stenosis undergoing CEA
and may negatively impact the risks of HP and CHS. These concerns
apply even more consistently to carotid stenting (CAS) procedures
in which the haemodynamic burden from carotid intervention is
greater and the potential for cerebral haemorrhage has been sug-
gested to be higher than CEA.
There is large need of further research similar to that of
Pennekamp et al. to clarify the dark sides of CEA and CAS
potentially leading to catastrophic outcomes. Even if uncommon,
these complications are of main impact especially as today we
often operate on patients with asymptomatic carotid disease
and for whom the overall beneﬁt of carotid revascularisation is
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